What is LambdaVision?
LambdaVision is at the forefront of developing a revolutionary protein-based artificial retina designed to restore meaningful vision for individuals suffering from blinding retinal degenerative diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Their patent-protected technology ingeniously mimics the light-absorbing capabilities of natural human photoreceptor cells by utilizing photoactive proteins. This approach aims to activate residual neuroreceptors in the retinas of blind patients, offering a novel therapeutic pathway. The company's current lifecycle stage, indicated by its major enterprise-level funding, suggests a transition from development to scaling its innovative solutions.
How much funding has LambdaVision raised?
LambdaVision has raised a total of $7.5M across 2 funding rounds:
Series A
$500K
Seed
$7M
Series A (2017): $500K with participation from Connecticut Innovations
Seed (2025): $7M led by Seraphim Capital and Seven Seven Six
Key Investors in LambdaVision
Seraphim Capital
Seraphim Capital is a global leader in SpaceTech investment, focusing on visionary space entrepreneurs and deeptech ventures. They provide funding, expertise, and a global network to accelerate innovative ideas in space.
Seven Seven Six
Seven Seven Six is an early-stage venture capital firm that focuses on innovation at the intersection of product and people, utilizing a proprietary operating system to enhance scalability and support for its portfolio companies.
Connecticut Innovations
Connecticut Innovations is the state's strategic venture capital arm, providing equity and debt financing, strategic guidance, and connections to help innovative companies in sectors like AI/quantum, climate tech, and biosciences scale.
What's next for LambdaVision?
With this substantial capital infusion, LambdaVision is poised to accelerate its research and development efforts, potentially moving towards clinical trials and eventual commercialization of its artificial retina technology. The strategic investment signals strong confidence from backers in the company's potential to address a significant unmet medical need. Future endeavors will likely focus on scaling manufacturing processes, navigating regulatory pathways, and expanding the team to support broader market penetration. Continued strategic partnerships and further investment rounds may be anticipated as the company progresses towards its goal of restoring sight.
See full LambdaVision company page
